Redcare Pharmacy Shares Defy Strong Performance with Steep Decline

Investors are delivering a harsh verdict on Redcare Pharmacy despite the company reporting exceptional operational results. The online pharmacy’s stock has plunged 12% within a single week, creating a puzzling disconnect between financial performance and market sentiment that demands examination.

Regulatory Breakthrough and Expansion Strategy

A significant development emerged in July 2025 when Germany’s Federal Constitutional Court confirmed that online pharmacies operating across EU borders aren’t subject to fixed medication pricing regulations. This regulatory clarity provides Redcare with a substantial competitive advantage in the European marketplace.

Concurrently, the company is making substantial investments in automation technology. By early 2027, Redcare plans to double its operational capacity while reducing labor costs per order by an impressive 70%. This capital-light approach could significantly enhance profitability as transaction volumes increase.

Prescription Business Reaches New Heights

The core of Redcare’s operations shows remarkable acceleration. The company’s German prescription business has achieved extraordinary growth, surging 122% compared to the previous year. During the third quarter alone, revenue from prescription medications reached €126 million, representing an acceleration from the preceding quarter.

Throughout the entire DACH region, the business demonstrated robust performance with growth of 26.7%. Particularly noteworthy achievements include the addition of 200,000 new active customers and a recovery in the Net Promoter Score to 72 points—marking the second-best third-quarter result in the company’s history.

Should investors sell immediately? Or is it worth buying Redcare Pharmacy?

Market Experts Maintain Confidence

Despite the stock’s downward trajectory, eight financial analysts have reaffirmed their revenue projections of €3.57 billion for 2026, which would represent 27% growth. More intriguing is the wide dispersion in price targets among these experts, ranging from €82 to €214 per share—an unusually broad spectrum reflecting substantial market uncertainty.

Company leadership has simultaneously confirmed its full-year 2025 forecast across all metrics. Expectations remain elevated, including revenue growth exceeding 25%, German prescription sales surpassing €500 million, and an EBITDA margin between 2.0% and 2.5%.

Untapped Market Potential

The company’s future opportunity appears substantial when examining market dynamics. Germany’s online pharmacy sector represents a €55 billion market, yet only 1-2% of prescription transactions currently occur through digital channels. This contrasts sharply with over-the-counter medications, where online penetration has already reached 23-25%.

This divergence between strong fundamental performance and declining share price presents investors with a compelling question: does the current downturn represent a buying opportunity? The underlying business metrics tell a positive story even as the stock experiences pressure—an uncommon situation that warrants close attention from market participants.